Emergent BioSolutions (EBS) EBITDA Margin (2011 - 2026)
Emergent BioSolutions (EBS) posted quarterly EBITDA Margin of 6.73% for Q1 2026, down 1573.0% year-over-year from 0.46% in Q1 2025, and up 135.85% quarter-over-quarter from 18.76% in Q4 2025.
Emergent BioSolutions (EBS) EBITDA Margin (2011 - 2026) Analysis & Trends
Emergent BioSolutions' EBITDA Margin history runs 16 years deep, the most recent figure standing at 6.73% for Q1 2026.
- In Q1 2026, EBITDA Margin fell 1573.0% year-over-year to 6.73%; the TTM figure through Mar 2026 stood at 8.97% (up 2193.0% YoY), while the FY2025 annual figure was 13.47%, up 2389.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 6.73%, up from 18.76% in the prior quarter.
- The five-year high for EBITDA Margin was 33.1% in Q3 2025, with the low at 407.0% in Q2 2024.
- The 5-year median for EBITDA Margin is 15.84% (2023), against an average of 39.92%.
- The sharpest annual moves came in 2024 and 2025: EBITDA Margin slumped 32032 bps in 2024, then surged 40814 bps in 2025.
- Emergent BioSolutions' EBITDA Margin stood at 16.75% in 2022, then advanced by 5 bps to 15.84% in 2023, then jumped by 69 bps to 4.88% in 2024, then tumbled by 285 bps to 18.76% in 2025, then jumped by 136 bps to 6.73% in 2026.
- Business Quant data shows EBS's EBITDA Margin at 6.73% in Q1 2026, 18.76% in Q4 2025, and 33.1% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -5.58% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 33.91% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 16.51% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 42.23% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 0.17% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 15.80% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 18.13% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn | -53.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -53.39% |
| Mar 31, 2026 | 6.73% |
| Dec 31, 2025 | -18.76% |
| Sep 30, 2025 | 33.10% |
| Jun 30, 2025 | 1.14% |
| Mar 31, 2025 | 22.46% |
| Dec 31, 2024 | -4.88% |
| Sep 30, 2024 | 21.95% |
| Jun 30, 2024 | -407.00% |
| Mar 31, 2024 | 13.25% |
| Dec 31, 2023 | -15.84% |
| Sep 30, 2023 | -89.50% |
| Jun 30, 2023 | -86.68% |
| Mar 31, 2023 | -89.84% |
| Dec 31, 2022 | -16.75% |
| Sep 30, 2022 | -18.88% |
| Jun 30, 2022 | -31.45% |
| Mar 31, 2022 | 2.26% |
| Dec 31, 2021 | 39.13% |
| Sep 30, 2021 | -15.61% |